Antithrombotic agents in coronary artery disease.

Abbreviations: ADP 5 adenosine diphosphate; AMI 5 acute myocardial infarction; APSAC 5 anistreplase; APTT 5 activated partial thromboplastin time; ASA 5 acetylsalicylic acid; ASPECT trial 5 Anticoagulation in the Secondary Prevention of Events in Coronary Thrombosis; CAPTURE trial 5 c7E3 Fab Antiplatelet Therapy in Unstable Refractory Ischemia; CHAMP study 5 Combined Hemotherapy and Mortality Prevention; CHF 5 congestive heart failure; CI 5 confidence interval; CK 5 creatine kinase; EF 5 ejection fraction; ESSENCE trial 5 Enoxaparin in Unstable Angina and Non-Q-Wave Myocardial Infarction; FRAXIS trial 5 Fraxiparine in Ischemic Syndrome; FRIC trial 5 Fragmin in Coronary Artery Disease; FRISC trial 5 Fragmin during Instability in Coronary Artery Disease; GP 5 glycoprotein; GUSTO trial 5 Global Use of Strategies to Open Occluded Coronary Arteries; HOT 5 Hypertension Optimal Treatment; IHD 5 ischemic heart disease; INR 5 international normalized ratio; ISIS 5 International Studies of Infarct Survival; LMWH 5 low-molecular-weight heparin; LV 5 left ventricle, ventricular; MI 5 myocardial infarction; NS 5 not significant; OASIS study 5 Organization to Assess Strategies for Ischemic Syndromes; OR 5 odds ratio; PRISM trial 5 Platelet Receptor Inhibition for Ischemic Syndrome Management; PTCA 5 percutaneous transluminal coronary angioplasty; PURSUIT trial 5 Platelet IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin; RR 5 relative risk; RRR 5 relative risk reduction; rtPA 5 recombinant tissue-type plasminogen activator; SC 5 subcutaneous, subcutaneously; SCATI group 5 Studio sulla Calciparina nell’Angina e nella Thrombosi Ventriculare Nell’Infarto; SK 5 streptokinase; TIA 5 transient ischemic attack; TIMI 5 Thrombolysis in Myocardial Infarction; TPT 5 Thrombosis Prevention Trial; 2D 5 two-dimensional; W 5 active warfarin and placebo aspirin; WA 5 active warfarin and active aspirin; WARIS 5 Warfarin Reinfarction Study (CHEST 2001; 119:228S–252S)